Dr. Lindsey's Multiple Sclerosis Website

Interferon versus Glatiramer--update 11/07

Active Clinical Trials at UT 2018
ACTRIMS Forum 2017
Tecfidera update September, 2016
AAN 2015
AAN 2014
Current Treatments (updated 7/7/13)
Gilenya (updated 4/20/2012)
Tysabri and PML
Recent and current research
Old meetings
New diagnosis of MS
Multiple Sclerosis Basic Information
Interferon versus Glatiramer--update 11/07
Talk on stem cells--2/13/08
About Dr. Lindsey
Research Interests
Clinic information
Contact Us

The interferons and glatiramer are the two treatments used most often for relapsing-remitting MS.  Their effectiveness has been compared in two recent studies.

We have been using interferon and glatiramer for the last 15 years for treatment of MS.  In the studies of the effectiveness of each drug, they reduced the number of relapses by about 30% compared with placebo.  Direct comparisons of high dose interferon (Betaseron, Rebif) with low dose interferon (Avonex) have shown the higher doses are more effective.  Until now, there have not been any well done comparisons of the relative effectiveness of interferon and glatiramer.  Now preliminary results from two studies, one comparing Rebif and Copaxone and the other comparing Betaseron and Copaxone, have been reported. 
REGARD study:  These results were reported at the ECTRIMS meeting in October 2007.  This was a large clinical study comparing the effectiveness of Rebif, an interferon, with Copaxone, glatiramer acetate.  The trial was funded by EMD Serono, the makers of Rebif.  There were 386 people on Rebif and 378 on Copaxone followed for 96 weeks.  The main outcome measure was the time to first relapse.  They did not find any difference between the two treatments, but the number of relapses observed was less than expected.  The number of patients who completed the study was similar in both groups. The MRI measures favored Rebif, which is expected since interferon has a larger effect on MRI activity than glatiramer does. 
BEYOND study:  This study has only been reported as a press release on the Bayer website, so the data available are limited.  This study compared Betaseron, double-dose Betaseron, and Copaxone in 2,244 patients.  The main outcome measure was the risk for relapse, and there was no difference between the three groups.  The number of people completing the study was similar in each group.  MRI results are not reported yet. 
Conclusions:  There is not a significant difference in the effectiveness of interferon and glatiramer in their ability to prevent relapses.  There also does not appear to be much difference in the tolerability of the two treatments.  The side effects are quite different, but the number of people staying on therapy is similar.  Either interferon or glatiramer is a good choice for relapsing-remitting MS, and there is no reason to prefer one over the other based on effectiveness or tolerability.  The currently marketed dose of Betaseron is sufficient to get the maximum benefit. 
We should have more detailed information from both of these studies in the next few months. 

J. William Lindsey, MD
University of Texas Multiple Sclerosis Research Group
Houston, Texas

copyright 2007-2018 John William Lindsey